Scientists from the National Institute of Aging (NIA) at National Institutes of Health (NIH) in collaboration with Tawain's National Health Research Institutes and Case Western Reserve University School of Medicine worked with Peptron Inc. a Korean-based public pharmaceutical company to develop a sustained-release formulation (called SR-exenatide) that shows promise against Parkinson's disease.
Parkinson's disease is a chronic and progressive movement disorder. It is the second most common neurodegenerative disease, afflicting nearly one million people in the United States.
Peptron recently expanded an exclusive license of intellectual property from the NIH that covers the delivery and use of SR-exenatide for the treatment of neurodegenerative disorders. In addition, the company has begun operations of a manufacturing facility to produce SR-exenatide for a Phase 2 clinical trial in Parkinson's disease and for further evaluation of SR-exenatide for the treatment of Alzheimer's disease and related disorders.
For further infomration regarding the NIA collaboration with Peptron, please visit thier website by clicking here